immune checkpoint inhibitors

May 8, 2020May 8, 2020

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

News

Men with metastatic castration-resistant prostate cancer (mCRPC) showing evidence of active immune responses in their tumors live longer without disease progression after being treated with Yervoy (ipilimumab), a Phase 2 ... Read more

April 21, 2017April 21, 2017

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

News

Combining BioXcel‘s BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company. Dr. Luca Rastelli, BioXCel’s vice-president for oncology research ... Read more

March 17, 2017March 17, 2017

Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds

News

Combining immune checkpoint inhibitors with drugs that target a population of myeloid-derived suppressor cells (MDSCs) may offer hope for men with metastatic prostate cancer who no longer respond to androgen deprivation therapy (ADT). ... Read more